SIRPA and glioblastoma: Willingham et al. showed that administration of B6H12, an anti-CD47 antibody, to mice carrying human xenograft tumors, including glioblastoma, resulted in increased phagocytosis of tumor cells by macrophages that exerted a SIRPα murine form that was incapable of binding CD47.